"Hlavn\u00EDm z\u00E1m\u011Brem projektu je validace a studium mechanismu \u00FA\u010Dinku n\u00E1mi ned\u00E1vno odhalen\u00FDch genetick\u00FDch marker\u016F, tj. genov\u00E9 exprese v n\u00E1dorov\u00FDch tk\u00E1n\u00EDch a genov\u00FDch polymorfism\u016F v krvi pacient\u016F l\u00E9\u010Den\u00FDch standardn\u00ED, p\u0159edev\u0161\u00EDm neoadjuvantn\u00ED chemoterapi\u00ED karcinomu prsu. C\u00EDlem jsou markery metabolismu (nap\u0159.: cytochromy P450, NQO, SOD, dr\u00E1ha 5-fluorouracilu) a transportu (ABC a SLC transport\u00E9ry) cytostatik ve vztahu ke klinicko-patologick\u00FDm charakteristik\u00E1m, p\u0159e\u017E\u00EDv\u00E1n\u00ED a \u00FA\u010Dinnosti l\u00E9\u010Dby pacientek. U \u00FAsp\u011B\u0161n\u011B validovan\u00FDch kandid\u00E1t\u016F budeme studovat mechanismus jak\u00FDm markery p\u016Fsob\u00ED korelac\u00ED genov\u00E9 exprese s hladinou proteinu a zji\u0161t\u011Bn\u00EDm v\u00FDznamu genotypu. Budeme studovat i methylaci regula\u010Dn\u00EDch oblast\u00ED kandid\u00E1tn\u00EDch gen\u016F jako nez\u00E1visl\u00FD marker. Zvl\u00E1\u0161tn\u00ED pozornost budeme v\u011Bnovat studiu agresivn\u00EDch triple-negative karcinom\u016F u pacient\u016F i na modelov\u00FDch bun\u011B\u010Dn\u00FDch lini\u00EDch s t\u00EDmto fenotypem. U bun\u011B\u010Dn\u00FDch model\u016F se pokus\u00EDme vysledovat mechanismus nez\u00E1vislou cestou v\u010Detn\u011B hled\u00E1n\u00ED vztahu mezi typem l\u00E9\u010Diva, jeho d\u00E1vkou a \u00FA\u010Dinkem" . . " neoadjuvant" . "0"^^ . . "2014-03-21+01:00"^^ . "NT13679" . "2012-04-01+02:00"^^ . "3"^^ . "1"^^ . . "Studie mechanismu \u00FA\u010Dink\u016F biomarker\u016F koreluj\u00EDc\u00EDch s v\u00FDsledkem l\u00E9\u010Dby karcinomu prsu" . . . . "breast; carcinoma; neoadjuvant; therapy; prediction; marker"@en . "3"^^ . "2015-12-31+01:00"^^ . . "3"^^ . "2015-01-22+01:00"^^ . "http://www.isvav.cz/projectDetail.do?rowId=NT13679"^^ . " carcinoma" . . " therapy" . . . "breast" . . . "Validation of differences in expression of previously identified genetic markers between patients with breast carcinoma treated by standard, mainly neoadjuvant chemotherapy, will be the main goal of this project. Markers representing metabolism (e.g. cytochromes P450, SOD, NQO) and transport (ABC and SLC transporters) of anticancer drugs will be studied in relation to clinico-pathological characteristics, therapy outcome and survival of patients. Mechanism of action of validated markers will be studied by correlation of gene expression with protein level and analysis of genotype. Methylation of regulatory elements of candidate genes will be studied as independent prognostic or predictive marker. Special attention will be paid to the study of aggressive triple-negative tumors in both patients and cell models. Breast tumor cell line models differing in expression of receptors (estrogen, progesterone, ERBB2) will be employed for elucidation of mechanisms of action of biomarkers by alternative approach."@en . . . . "Study of mechanism of action of biomarkers correlating with breast cancer therapy outcome"@en . " prediction" . . . . .